Health Economics›Gastrointestinal stromal tumor›Metastatic or unresectable disease third-line

Metastatic or unresectable disease third-line

Gastrointestinal stromal tumor · 4 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cabozantinib monotherapy Variant #01	—	R 151 638	28d	~9.3 mo	~16.2 mo	~2	~R 303 276 PFS proxy · indirect	17
Regorafenib monotherapy Variant #01	—	R 132 655	28d	5.2 mo	—	2	R 265 310 PFS proxy	2
Pazopanib monotherapy Variant #01	—	R 22 754	28d	3.4 mo	—	2	R 45 507 PFS proxy	1
Sorafenib monotherapy Variant #04	—	R 16 002	28d	—	—	~2	~R 32 005 PFS proxy · indirect	1

4 of 4 regimens shown